OG cancer is a big killer

Oesophageal cancer
Stomach cancer
What is already known on this subject
• Oesophageal and Gastric Cancers are 13 th and 16 th commonest cancers in the UK.
• Every year 6900 pts are diagnosed with Oesophageal and 5700 pts with gastric cancer; 10,000 pts die annually.
• Current UK referral guidelines for gastroscopy focus on alarm symptoms • These symptoms have poor sensitivity and specificity for early cancer and are associated with advanced disease • To assess the effectiveness of the OG cancer campaign in detection of OG Cancers in South Durham (Darlington Memorial and Bishop Auckland Hospitals)
• To analyse the Service impact of the Campaign on the workload in Endoscopy Units during the campaign esp. for routine GP referrals
Methods
• Upper GI endoscopy data captured as additions to gastroscopy waiting lists over 2 periods:
-During OG campaign -Feb/March 2015 -4 months after campaign -June/July 2015
• Data included all new referrals from GPs for upper gastrointestinal symptoms only.
• Exclusion criteria: Variceal screening, Barrett's surveillance, pts already under secondary care
Results ( • Non-campaign period: 1 gastric adenocarcinoma (0.81% of 2WW referrals)
• Presenting Symptoms: Dysphagia and weight loss or dyspepsia with weight loss.
• 2 non-OG cancers were picked up during non-campaign 2WW referral (normal OGD, abnormal imaginglymphoma, metastatic adenocarcinoma of unknown origin).
Impact on endoscopy unit workload
• Impact on waiting times:
• Urgent referrals: No impact, average waiting time 29-42 days for both periods.
• Routine referrals: Increase in average waiting time from 29-42 days (non-campaign period) to 43-56 days (campaign period).
Similar results from other areas 
Conclusion
• A national OG cancer awareness campaign produces a 2.2 times increase in referrals for gastroscopy.
• Significant impact on routine endoscopy waiting times.
• The OG cancer diagnosis yield is small. Predicted cost per cancer diagnosed is well over £30,000 (NICE approved QALY threshold for affordability of an investigation)
• Cost benefit of the campaign is unaffordable for Early OG cancer diagnosis in the present form.
